Cargando…
Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth
17-alpha-hydroxyprogesterone caproate (17P) has been in use for prevention of recurrent preterm birth since 2003 when the Meis trial was published. A requirement for Food and Drug Administration approval of 17P was a confirmatory trial, called “PROLONG”, which was recently completed, but did not rep...
Autores principales: | Sibai, Baha, Saade, George R., Das, Anita F., Gudeman, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049867/ https://www.ncbi.nlm.nih.gov/pubmed/33057132 http://dx.doi.org/10.1038/s41372-020-00849-y |
Ejemplares similares
-
Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth
por: Vidaeff, Alex C, et al.
Publicado: (2013) -
Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth
por: Rouholamin, Safoura, et al.
Publicado: (2015) -
The Influence of Prior Obstetrical History on Current 17-Hydroxyprogesterone Caproate Use
por: Ransom, Carla E., et al.
Publicado: (2011) -
Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention
por: Garcia, Stephanie M., et al.
Publicado: (2021) -
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial
por: Price, Joan T., et al.
Publicado: (2019)